Evolocumab 140 MG/ML
Evolocumab 140 MG/ML is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
4 of 4 finished
0.0%
0 ended early
1
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study
EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial
In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction
Clinical Trials (6)
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study
EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial
In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction
EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6